Medifast Gestione
Gestione criteri di controllo 3/4
Medifast Il CEO è Dan Chard, nominato in Oct2016, e ha un mandato di 8.08 anni. la retribuzione annua totale è $ 7.04M, composta da 14.2% di stipendio e 85.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.46% delle azioni della società, per un valore di $ 2.83M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.7 anni e 8.1 anni.
Informazioni chiave
Dan Chard
Amministratore delegato
US$7.0m
Compenso totale
| Percentuale dello stipendio del CEO | 14.2% |
| Mandato del CEO | 8.1yrs |
| Proprietà del CEO | 1.5% |
| Durata media del management | 4.7yrs |
| Durata media del Consiglio di amministrazione | 8.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Nov 06Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Sep 03Medifast Business Continues To Shrink, Stock Still Risky
Aug 27Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Jun 26Medifast: Significant Undervaluation Even As Struggles Persist
May 24At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
May 24Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
May 06The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
May 01Medifast: Cheap Valuation, Uncertain Future
Mar 20Medifast Is Getting Attractive
Mar 07Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Feb 22Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Jan 20Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Dec 09Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Nov 24Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Nov 21Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Nov 09Medifast: The Race To Weight-Loss Drugs Not Lost Yet
Oct 09Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Aug 04Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?
Jul 26In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Jul 21Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Jul 05Medifast: In Survival Mode Against Diet Pills And The Recession
Jun 14Medifast Holds Value During Headwinds
May 28Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M
Feb 21Medifast: A Low Earnings Multiple Despite Strong Financial Performance
Feb 07At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Jan 19Medifast declares $1.64 dividend
Dec 08A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Dec 01Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 10One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates
Nov 08Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy
Nov 06What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Oct 20We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt
Sep 18Medifast declares $1.64 dividend
Sep 08Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?
Sep 02Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good
Aug 21Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$7m |
| Jun 30 2024 | n/a | n/a | US$29m |
| Mar 31 2024 | n/a | n/a | US$68m |
| Dec 31 2023 | US$7m | US$1m | US$99m |
| Sep 30 2023 | n/a | n/a | US$120m |
| Jun 30 2023 | n/a | n/a | US$133m |
| Mar 31 2023 | n/a | n/a | US$142m |
| Dec 31 2022 | US$6m | US$981k | US$144m |
| Sep 30 2022 | n/a | n/a | US$151m |
| Jun 30 2022 | n/a | n/a | US$157m |
| Mar 31 2022 | n/a | n/a | US$165m |
| Dec 31 2021 | US$7m | US$914k | US$164m |
| Sep 30 2021 | n/a | n/a | US$158m |
| Jun 30 2021 | n/a | n/a | US$150m |
| Mar 31 2021 | n/a | n/a | US$125m |
| Dec 31 2020 | US$6m | US$909k | US$103m |
| Sep 30 2020 | n/a | n/a | US$95m |
| Jun 30 2020 | n/a | n/a | US$76m |
| Mar 31 2020 | n/a | n/a | US$76m |
| Dec 31 2019 | US$5m | US$843k | US$78m |
| Sep 30 2019 | n/a | n/a | US$74m |
| Jun 30 2019 | n/a | n/a | US$72m |
| Mar 31 2019 | n/a | n/a | US$64m |
| Dec 31 2018 | US$2m | US$675k | US$56m |
| Sep 30 2018 | n/a | n/a | US$47m |
| Jun 30 2018 | n/a | n/a | US$40m |
| Mar 31 2018 | n/a | n/a | US$34m |
| Dec 31 2017 | US$2m | US$650k | US$28m |
Compensazione vs Mercato: La retribuzione totale di Dan ($USD 7.04M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.47M ).
Compensazione vs guadagni: La retribuzione di Dan è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Dan Chard (59 yo)
8.1yrs
Mandato
US$7,039,062
Compensazione
Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman & CEO | 8.1yrs | US$7.04m | 1.46% $ 2.8m | |
| Chief Financial Officer | 4.3yrs | US$2.01m | 0.092% $ 177.1k | |
| Chief Business Operations Officer | 2.8yrs | US$1.61m | 0.12% $ 226.5k | |
| Executive VP | 13yrs | US$1.63m | 0.12% $ 225.5k | |
| Chief Field Operations Officer | 5.8yrs | US$1.70m | 0.095% $ 184.4k | |
| VP of Finance & Chief Accounting Officer | 3.2yrs | Nessun dato | 0.0052% $ 10.1k | |
| Vice President of Investor Relations | 1.7yrs | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 5.1yrs | Nessun dato | Nessun dato |
4.7yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di MED è considerato esperto (durata media dell'incarico 4.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman & CEO | 8.1yrs | US$7.04m | 1.46% $ 2.8m | |
| Lead Independent Director | 9.4yrs | US$263.42k | 0.15% $ 283.3k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 6.4yrs | US$249.72k | 0.079% $ 152.1k | |
| Independent Director | 5.4yrs | US$249.72k | 0.059% $ 113.5k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 6.4yrs | US$219.61k | Nessun dato | |
| Chairman of Scientific Advisory Board | 16yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 9.4yrs | US$252.44k | 0.073% $ 141.4k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato |
8.1yrs
Durata media
62.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MED sono considerati esperti (durata media dell'incarico 8.1 anni).